Anna Stanhewicz, PhD
15
10
12
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
67%
2 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM
Role: lead
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
Role: lead
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
Role: lead
Antidepressant Therapy for Improved Blood Vessel Health After Preeclampsia
Role: lead
Vascular Effects of High-Salt After Preeclampsia
Role: lead
MR and Inflammation After Preeclampsia
Role: lead
The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy
Role: lead
Daily Aspirin Treatment After Preeclampsia
Role: lead
Sex Differences in the Vascular Effects of E-cigarette Use
Role: lead
Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia
Role: lead
Losartan for Improved Vascular Endothelial Function After Preeclampsia
Role: lead
Prenatal Aspirin and Postpartum Vascular Function
Role: lead
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
Role: lead
Sex Differences in the Dilatory Response of Compound 21
Role: lead
Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia
Role: lead
All 15 trials loaded